{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:01:56Z","timestamp":1780761716577,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH","award":["R01 EB027498-A1"],"award-info":[{"award-number":["R01 EB027498-A1"]}]},{"name":"NIH","award":["U01 CA238444-01A1"],"award-info":[{"award-number":["U01 CA238444-01A1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1245\/s10434-026-19652-8","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T16:57:37Z","timestamp":1776358657000},"page":"6099-6109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Lauren E.","family":"Schleimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Rousian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Alessandris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Kalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Poletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Jolissaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorien","family":"van Verschuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Drebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Peter","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"5","key":"19652_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446r","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2015-0446r.","journal-title":"Oncologist."},{"issue":"1","key":"19652_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396. https:\/\/doi.org\/10.1097\/SLA.0b013e318176c4d3.","journal-title":"Ann Surg."},{"issue":"14","key":"19652_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med."},{"issue":"9","key":"19652_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2016.64","volume":"114","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Palmer D, et al. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer. 2016;114(9):965\u201371. https:\/\/doi.org\/10.1038\/bjc.2016.64.","journal-title":"Br J Cancer."},{"issue":"8","key":"19652_CR5","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):EVIDoa2200015. https:\/\/doi.org\/10.1056\/EVIDoa2200015.","journal-title":"NEJM Evid."},{"issue":"10391","key":"19652_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet."},{"issue":"2","key":"19652_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/jnci\/djz071","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst. 2020;112(2):200\u201310. https:\/\/doi.org\/10.1093\/jnci\/djz071.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"19652_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3718.","journal-title":"JAMA Oncol."},{"issue":"3\u20134","key":"19652_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000324704","volume":"80","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, Schwartz L, G\u00f6nen M, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3\u20134):153\u20139. https:\/\/doi.org\/10.1159\/000324704.","journal-title":"Oncology."},{"issue":"9","key":"19652_CR10","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395. https:\/\/doi.org\/10.1093\/annonc\/mdp029.","journal-title":"Ann Oncol."},{"key":"19652_CR11","doi-asserted-by":"publisher","unstructured":"Franssen S, Rousian M, Nooijen LE, et al. Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: a multicenter phase II trial. J Clin Oncol. 2024;42(3_suppl):433-433. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.433","DOI":"10.1200\/JCO.2024.42.3_suppl.433"},{"issue":"1","key":"19652_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol."},{"issue":"2","key":"19652_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/hep.32258","volume":"75","author":"G Sapisochin","year":"2022","unstructured":"Sapisochin G, Ivanics T, Heimbach J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? Hepatology. 2022;75(2):455\u201372. https:\/\/doi.org\/10.1002\/hep.32258.","journal-title":"Hepatology."},{"issue":"3","key":"19652_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ajt.16906","volume":"22","author":"RR McMillan","year":"2022","unstructured":"McMillan RR, Javle M, Kodali S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022;22(3):823\u201332. https:\/\/doi.org\/10.1111\/ajt.16906.","journal-title":"Am J Transplant."},{"key":"19652_CR15","unstructured":"ClinicalTrials.gov. Liver transplantation in intrahepatic cholangiocarcinoma. Accessed September 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06140134"},{"key":"19652_CR16","unstructured":"ClinicalTrials.gov. Liver transplant for stable, advanced intrahepatic cholangiocarcinoma. Accessed September 20, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04195503"},{"key":"19652_CR17","unstructured":"ClinicalTrials.gov. Liver transplantation for non-resectable intrahepatic cholangiocarcinoma: a prospective exploratory trial (TESLA trial). Accessed September 22, 2024. https:\/\/clinicaltrials.gov\/study\/NCT04556214"},{"key":"19652_CR18","unstructured":"ClinicalTrials.gov. LIver transplantation for non-resectable intrahepatic cholangiocarcinoma (LIRICA). Accessed September 22, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06098547"},{"issue":"6","key":"19652_CR19","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313. https:\/\/doi.org\/10.1038\/nm.4333.","journal-title":"Nat Med."},{"key":"19652_CR20","doi-asserted-by":"publisher","unstructured":"Cevallos M, Egger M. STROBE (strengthening the reporting of observational studies in epidemiology). In: Moher D, Altman DG, Schulz KF, Simera I, Wager E, eds. Guidelines for reporting health research: a user\u2019s manual. Wiley; 2014:169-79. https:\/\/doi.org\/10.1002\/9781118715598.ch17","DOI":"10.1002\/9781118715598.ch17"},{"key":"19652_CR21","unstructured":"Ghobrial RM. Personal communication. September 21, 2023."},{"issue":"3","key":"19652_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology. 2021;74(3):1429\u201344. https:\/\/doi.org\/10.1002\/hep.31829.","journal-title":"Hepatology."},{"key":"19652_CR23","unstructured":"Sapisochin G. Liver transplant for stable, advanced intrahepatic cholangiocarcinoma. ClinicalTrials.gov identifier:\u00a0NCT04195503. ClinicalTrials.gov. December 12, 2019. Accessed March 12, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04195503"},{"issue":"7","key":"19652_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamasurg.2022.1298","volume":"157","author":"S Franssen","year":"2022","unstructured":"Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157(7):590\u20136. https:\/\/doi.org\/10.1001\/jamasurg.2022.1298.","journal-title":"JAMA Surg."},{"issue":"14","key":"19652_CR25","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-21-0412","volume":"27","author":"JS Jolissaint","year":"2021","unstructured":"Jolissaint JS, Soares KC, Seier KP, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis: treatment-related outcomes and the role of tumor genomics in patient selection. Clin Cancer Res. 2021;27(14):4101\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0412.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"19652_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1245\/s10434-020-09001-8","volume":"28","author":"JJA Vugts","year":"2021","unstructured":"Vugts JJA, Gaspersz MP, Roos E, et al. Eligibility for liver transplantation in patients with perihilar cholangiocarcinoma. Ann Surg Oncol. 2021;28(3):1483\u201392. https:\/\/doi.org\/10.1245\/s10434-020-09001-8.","journal-title":"Ann Surg Oncol."},{"key":"19652_CR27","doi-asserted-by":"publisher","unstructured":"Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88-98.e3; quiz e14. https:\/\/doi.org\/10.1053\/j.gastro.2012.04.008","DOI":"10.1053\/j.gastro.2012.04.008"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19652-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19652-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:23Z","timestamp":1780761143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19652-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19652"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19652-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V. P. Balachandran reports research funding from Genentech\/Roche and is an inventor on patent applications related to antigen cross-reactivity and neoantigen quality modelling. J Jolissaint reports Travel support\u2014Boston Scientific; Travel support\u2014Intuitive J. Drebin reports employment and leadership at American Regent (spouse) and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. A. C. Wei reports consulting roles at HistoSonic and institutional research funding from Ipsen. M. Gonen reports funding for travel, accommodations, and expenses from Genentech. B. Groot Koerkamp reports research funding in kind from Tricumed. B. Groot Koerkamp reports Speaker for Boston Scientific on HAIP chemotherapy and SIRT in 2026.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}